TVTX TRAVERE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, TRAVERE THERAPEUTICS INC reported revenue of $170M (up 48.2% from a year earlier), net income of −$34.8M and diluted EPS of −$0.37; over the last four quarters revenue was $591M and net income −$43.5M; for the fiscal year ended December 2025 revenue was $491M, up 110.5% on the year before.

TVTX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $491M, gross profit n/a, operating income −$62.8M, net income −$25.5M (margin -5.2%), EPS −$0.29
• Fiscal year ended Dec 2024: revenue $233M, gross profit n/a, operating income −$324M, net income −$322M (margin -137.9%), EPS −$4.08
• Fiscal year ended Dec 2023: revenue $145M, gross profit n/a, operating income −$388M, net income −$111M (margin -76.7%), EPS −$1.50
• Fiscal year ended Dec 2022: revenue $109M, gross profit n/a, operating income −$320M, net income −$278M (margin -254.4%), EPS −$4.37
• Fiscal year ended Dec 2021: revenue $132M, gross profit n/a, operating income −$199M, net income −$180M (margin -136.6%), EPS −$3.01

TVTX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $170M (up 48.2% year over year), net income −$34.8M, EPS −$0.37
• Quarter ended Mar 31, 2026: revenue $127M (up 55.6% year over year), net income −$37.1M, EPS −$0.40
• Quarter ended Dec 31, 2025 (from the annual report): revenue $130M (up 73.4% year over year), net income $2.73M, EPS $0.04
• Quarter ended Sep 30, 2025: revenue $165M (up 162.1% year over year), net income $25.7M, EPS $0.28
• Quarter ended Jun 30, 2025: revenue $114M (up 111.5% year over year), net income −$12.8M, EPS −$0.14
• Quarter ended Mar 31, 2025: revenue $81.7M (up 97.5% year over year), net income −$41.2M, EPS −$0.47
• Quarter ended Dec 31, 2024 (from the annual report): revenue $74.8M (up 66.0% year over year), net income −$60.3M, EPS −$0.71
• Quarter ended Sep 30, 2024: revenue $62.9M (up 69.6% year over year), net income −$54.8M, EPS −$0.70
• Quarter ended Jun 30, 2024: revenue $54.1M (up 68.1% year over year), net income −$70.4M, EPS −$0.91
• Quarter ended Mar 31, 2024: revenue $41.4M (up 33.9% year over year), net income −$136M, EPS −$1.76
• Quarter ended Dec 31, 2023: revenue $45.1M (up 53.6% year over year), net income −$90.2M, EPS −$1.18
• Quarter ended Sep 30, 2023: revenue $37.1M (up 32.1% year over year), net income $151M, EPS $1.97
• Quarter ended Jun 30, 2023: revenue $32.2M (up 12.4% year over year), net income −$85.6M, EPS −$1.13
• Quarter ended Mar 31, 2023: revenue $30.9M (up 31.9% year over year), net income −$86.3M, EPS −$1.27
• Quarter ended Dec 31, 2022: revenue $29.3M (up 176.4% year over year), net income −$65.8M, EPS −$1.03
• Quarter ended Sep 30, 2022: revenue $28.1M (down 58.8% year over year), net income −$69.7M, EPS −$1.09
• Quarter ended Jun 30, 2022: revenue $28.6M (down 47.6% year over year), net income −$67.0M, EPS −$1.05
• Quarter ended Mar 31, 2022: revenue $23.4M (down 50.6% year over year), net income −$76.0M, EPS −$1.20
• Quarter ended Dec 31, 2021 (from the annual report): revenue −$38.4M, net income −$51.6M, EPS −$0.82
• Quarter ended Sep 30, 2021: revenue $68.2M, net income −$35.6M, EPS −$0.59

TVTX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $37.8M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$237M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$280M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$186M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$14.8M, share buybacks n/a

TVTX balance sheet

• Jun 30, 2026: cash $118M, total assets $799M, total liabilities $775M, shareholders' equity $24.5M
• Mar 31, 2026: cash $78.4M, total assets $555M, total liabilities $456M, shareholders' equity $98.7M
• Dec 31, 2025: cash $93.0M, total assets $605M, total liabilities $490M, shareholders' equity $115M
• Sep 30, 2025: cash $111M, total assets $539M, total liabilities $465M, shareholders' equity $73.6M
• Jun 30, 2025: cash $75.2M, total assets $555M, total liabilities $523M, shareholders' equity $32.7M
• Mar 31, 2025: cash $61.9M, total assets $549M, total liabilities $516M, shareholders' equity $32.8M
• Dec 31, 2024: cash $58.5M, total assets $594M, total liabilities $535M, shareholders' equity $59.1M
• Sep 30, 2024: cash $36.4M, total assets $504M, total liabilities $535M, shareholders' equity −$30.5M

What is TVTX's revenue?

TRAVERE THERAPEUTICS INC reported $591M of revenue over its last four quarters, through June 30, 2026.

Is TVTX profitable?

No. TRAVERE THERAPEUTICS INC lost $43.5M over the last four quarters.

What is TVTX's EPS?

Diluted earnings per share over the last four quarters were −$0.45; −$0.37 in the latest quarter.

TVTX ownership and insider trades · All stocks